Last mentioned: Mar 25, 2026
End of Certainty Period
The 21-year structured resolution period is slated to conclude.
Phase III Initiation
First patient dosed in the pivotal Phase III clinical trial for endometriosis.
$7.25B Settlement Announced
Bayer agrees to a new $7.25 billion deal with a 21-year certainty plan.
Phase II Completion
Positive results from Phase II studies demonstrate pain reduction and safety.
Initial $10B Settlement
Bayer announces a massive settlement to resolve current claims, but future liability remains.
Licensing Agreement
Hope Medicine acquires global rights for HMI-115 from Bayer.
Monsanto Acquisition
Bayer completes $63 billion acquisition of Monsanto, inheriting Roundup litigation.
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Bayer has reached a $7.25 billion settlement agreement to resolve long-standing litigation surrounding its Roundup herbicide. The deal includes a 21-year framework designed to provide legal and financial certainty for the company following years of costly courtroom battles.
This page surfaces every story mentioning Bayer across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Bayer was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |